Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.

Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E.

Genome Med. 2018 Nov 29;10(1):93. doi: 10.1186/s13073-018-0605-7. Review.

2.

Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.

Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2016 Nov 15;14(1):313.

3.

Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic.

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S.

Ann Oncol. 2018 Nov 5. doi: 10.1093/annonc/mdy495. [Epub ahead of print]

PMID:
30395155
4.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

5.

Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.

Ma W, Gilligan BM, Yuan J, Li T.

J Hematol Oncol. 2016 May 27;9(1):47. doi: 10.1186/s13045-016-0277-y. Review.

6.

Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade.

Wang Z, Zhao J, Wang G, Zhang F, Zhang Z, Zhang F, Zhang Y, Dong H, Zhao X, Duan J, Bai H, Tian Y, Wan R, Han M, Cao Y, Xiong L, Liu L, Wang S, Cai S, Mok TSK, Wang J.

Cancer Res. 2018 Nov 15;78(22):6486-6496. doi: 10.1158/0008-5472.CAN-18-1814. Epub 2018 Aug 31.

PMID:
30171052
7.

Second- and third-generation drugs for immuno-oncology treatment-The more the better?

Dempke WCM, Fenchel K, Uciechowski P, Dale SP.

Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10. Review.

PMID:
28335888
8.

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S.

Oncoimmunology. 2015 Mar 19;4(5):e1001236. eCollection 2015 May. Review.

9.

Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.

Borcherding N, Kolb R, Gullicksrud J, Vikas P, Zhu Y, Zhang W.

J Mol Biol. 2018 Jul 6;430(14):2014-2029. doi: 10.1016/j.jmb.2018.05.030. Epub 2018 May 22. Review.

PMID:
29800567
10.

Immunotherapy: a new treatment paradigm in bladder cancer.

Davarpanah NN, Yuno A, Trepel JB, Apolo AB.

Curr Opin Oncol. 2017 Mar 16. doi: 10.1097/CCO.0000000000000366. [Epub ahead of print]

11.

Manipulation of the immune system for cancer defeat: a focus on the T cell inhibitory checkpoint molecules.

D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, Romano MF, Romano S.

Curr Med Chem. 2018 Nov 5. doi: 10.2174/0929867325666181106114421. [Epub ahead of print]

PMID:
30398102
12.

Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?

Music M, Prassas I, Diamandis EP.

Crit Rev Clin Lab Sci. 2018 Nov;55(7):466-479. doi: 10.1080/10408363.2018.1499706. Epub 2018 Oct 2.

PMID:
30277835
13.

Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.

Mushtaq MU, Papadas A, Pagenkopf A, Flietner E, Morrow Z, Chaudhary SG, Asimakopoulos F.

J Immunother Cancer. 2018 Jul 3;6(1):65. doi: 10.1186/s40425-018-0376-0. Review.

14.

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.

Santarpia M, González-Cao M, Viteri S, Karachaliou N, Altavilla G, Rosell R.

Transl Lung Cancer Res. 2015 Dec;4(6):728-42. doi: 10.3978/j.issn.2218-6751.2015.12.04. Review.

15.

The application of nanotechnology in immune checkpoint blockade for cancer treatment.

Deng H, Zhang Z.

J Control Release. 2018 Nov 28;290:28-45. doi: 10.1016/j.jconrel.2018.09.026. Epub 2018 Oct 1. Review.

PMID:
30287266
16.

A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.

Carosella ED, Ploussard G, LeMaoult J, Desgrandchamps F.

Eur Urol. 2015 Aug;68(2):267-79. doi: 10.1016/j.eururo.2015.02.032. Epub 2015 Mar 29. Review.

PMID:
25824720
17.

Next generation of immune checkpoint therapy in cancer: new developments and challenges.

Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y.

J Hematol Oncol. 2018 Mar 15;11(1):39. doi: 10.1186/s13045-018-0582-8. Review.

18.
19.

Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.

Maccalli C, Parmiani G, Ferrone S.

Immunol Invest. 2017 Apr;46(3):221-238. doi: 10.1080/08820139.2017.1280051. Epub 2017 Mar 13. Review.

PMID:
28287848
20.

Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma.

Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C, Hennart B, Allorge D, van Geel N, Van Gele M, Brochez L.

Oncoimmunology. 2015 Apr 2;4(3):e982382. eCollection 2015 Mar.

Supplemental Content

Support Center